Europe Startup Funding Rounds
Startups raising capital across Europe. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 1,508 Jan 1 – Oct 26, 2026
- Disclosed funding
- $63.6B 1219 disclosed amounts
- Median round
- $6.8M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 QambriaCompany profile Qambria builds software that connects quantum processors to high-performance computing systems, helping developers run hybrid quantum-classical workloads with low-latency control. Qambria builds software that connects quantum processors to high-performance computing systems, helping developers run hybrid quantum-classical workloads with low-latency control. | CHF 2M | Pre-seed | Enterprise software | Switzerland | Investors | |
 WealthcomeCompany profile Wealthcome provides financial advisers with software to aggregate client assets, automate compliance and manage client relationships and advisory workflows. Wealthcome provides financial advisers with software to aggregate client assets, automate compliance and manage client relationships and advisory workflows. | €15M | Series B | Fintech | France | Investors | |
 50skillsCompany profile Employee and candidate workflows connecting HR systems, automation and human review. Employee and candidate workflows connecting HR systems, automation and human review. | $6M | Funding roundUndisclosed | Enterprise software | Iceland | Investors | |
QambriaCompany profile Qambria builds software that connects quantum processors to high-performance computing systems, helping developers run hybrid quantum-classical workloads with low-latency control. Qambria builds software that connects quantum processors to high-performance computing systems, helping developers run hybrid quantum-classical workloads with low-latency control. | CHF 850K | Innosuisse grantUndisclosed | Enterprise software | Switzerland | Investors | |
| KT Kasvu TherapeuticsCompany profile Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. | €30M | Series A | Biotech | Finland | Investors | |
 Reply NextCompany profile Reply Next helps multi-location brands manage reviews, ratings, customer messages and local search presence across digital platforms from one workspace. Reply Next helps multi-location brands manage reviews, ratings, customer messages and local search presence across digital platforms from one workspace. | €400K | Pre-seed | AI | Spain | Investors | |
 ClastixCompany profile Clastix builds Kubernetes infrastructure software, including Kamaji for hosted tenant control planes and kMetal for bare-metal cluster operations. Clastix builds Kubernetes infrastructure software, including Kamaji for hosted tenant control planes and kMetal for bare-metal cluster operations. | €2.9M | Seed | Developer tools | Italy | Investors | |
 KontextCompany profile Kontext provides runtime security for AI agents, evaluating tool calls against identity, intent and policy before execution and recording the authorization decision. Kontext provides runtime security for AI agents, evaluating tool calls against identity, intent and policy before execution and recording the authorization decision. | $4M | Seed | Cybersecurity | Germany | Investors | |
 DuquCompany profile Duqu provides short-term working capital to Dutch small businesses by advancing payment against verified business invoices while the business retains the customer receivable. Duqu provides short-term working capital to Dutch small businesses by advancing payment against verified business invoices while the business retains the customer receivable. | €1.5M | Pre-seed | Fintech | Netherlands | Investors | |
 StandardXCompany profile StandardX develops compact particle accelerators and isotope-refinery technology to produce isotopes for medical, industrial and energy applications. StandardX develops compact particle accelerators and isotope-refinery technology to produce isotopes for medical, industrial and energy applications. | £10M | Seed | Industrial tech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1High-Tech Gründerfonds
Rabot Energy, TODAY, Finches
39rounds4led - 2Antler
Jenz, Affinity Labs, CodeWall
26rounds0led - 3Y Combinator (YC)
HyLight, Sensible Biotechnologies, Revnu
22rounds1led - 4General Catalyst
Legora, Complir, Integral
21rounds1led - 5Index Ventures
Opply, Duvo, Spiko
21rounds2led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.